- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00744874
Ablation of the Pulmonary Veins for Paroxysmal Afib (MAP-PAF)
17. september 2018 opdateret af: Medtronic Cardiac Rhythm and Heart Failure
Multi-Array Ablation of the Pulmonary Veins for Paroxysmal Atrial Fibrillation
The purpose of this trial was to investigate and confirm the safety, efficacy, and efficiency of the Ablation Frontiers® Cardiac Ablation System when used in the treatment of paroxysmal atrial fibrillation.
(PAF)
Studieoversigt
Status
Afsluttet
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
This trial was a non-randomized, multi-center, prospective study of subjects with symptomatic, paroxysmal atrial fibrillation (PAF).
The purpose of this study was to investigate and confirm the safety, efficacy and efficiency of the Medtronic Ablation Frontiers® Cardiac Ablation System when used for the treatment of paroxysmal AF.
The trial was conducted over a 2 year period with enrollment occurring between 4 October 2007 and 1 December 2008.
Undersøgelsestype
Interventionel
Tilmelding (Faktiske)
55
Fase
- Fase 4
Kontakter og lokationer
Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.
Deltagelseskriterier
Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.
Berettigelseskriterier
Aldre berettiget til at studere
18 år til 70 år (Voksen, Ældre voksen)
Tager imod sunde frivillige
Ingen
Køn, der er berettiget til at studere
Alle
Beskrivelse
Inclusion Criteria:
History of symptomatic paroxysmal atrial fibrillation defined as:
- Self terminating AF lasting no more than 7 days
- AF events demostrating spontaneous conversion back to sinus rhythm
- Documentation of one or more events with PAF tracings by ECG, event recordings, pacemaker strips or monitor rhythm strips within the past year
- AF symptoms defined as the manisfestation of any of the following: Palpitations, Fatigue, Exertional dyspnea, effort intolerance
- Age between 18 and 70
- Willingness, ability and commitment to participate in baseline and follow-up evaluations for the full length of the study
Exclusion Criteria:
- Structural heart disease of clinical significance
- Prior ablation for arrhythmias other than AF within the past three months
- Prior left sided AF ablation
- Enrollment in any other ongoing arrhythmia study protocol
- Any ventricular tachyarrhythmias currently being treated where the arrhythmia or the management may interfere with this study
- Active infection or sepsis
- Any history of cerebral vascular disease including stroke or TIAs
- Pregnancy or lactation
- Untreatable allergy to contrast media
- Any diagnosis of atrial fibrillation secondary to electrolyte imbalance, thyroid disease, or any other reversible or non-cardiovascular causes
- History of blood clotting (bleeding or thrombotic) abnormalities
- Known sensitivities to heparin or warfarin
- Severe COPD (identified by an FEV1 < 1)
- Severe co morbidity or poor general physical/mental health that, in the opinion of the investigator, will not allow the patient to be a good study candidate (i.e. other disease processes, mental capacity, substance abuse, shortened life expectance, etc.)
Studieplan
Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Ablated Patients
Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
|
Patients with a history of symptomatic paroxysmal (self-terminating) AF and meeting all inclusion/exclusion criteria, as identified by the clinical investigator, will be enrolled in the study.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Number of Participants With Successful Pulmonary Vein Isolation
Tidsramme: 6 months
|
Acute effectiveness was defined as successful isolation of all pulmonary veins.
Pulmonary vein isolation was documented by the absence of pulmonary vein potentials when assessed by electrogram tracings in sinus rhythm using the PVAC catheter.
|
6 months
|
|
Chronic Effectiveness
Tidsramme: 6 months
|
The primary endpoint for chronic effectiveness was the evaluation of the proportion of subjects with treatment success computed at the 6 month visit.
In order to be classified as a chronic success, all subjects were required to meet the following criteria: Absence of clinically significant AF (greater than 60 seconds) or left atrial tachycardia recorded on a 7-day Holter, absence of symptomatic AF after a 3 month blanking period, off all Class I and III AADs at 6 months.
|
6 months
|
|
Acute Safety
Tidsramme: 7 days post procedure
|
The Acute Safety Endpoint was defined as the proportion of subjects with Serious Adverse Events (SAEs) that were procedure- and/or device-related within 7 days after the ablation procedure.
The relatedness of each event was assessed by the investigator at each site.
|
7 days post procedure
|
|
Chronic Safety
Tidsramme: 7 day post procedure to 6 months
|
The Chronic Safety Endpoint was the proportion of subjects with serious procedure- and/or device-related events in the 7 day to 6 month follow-up period post-ablation.
The relatedness of each event was assessed by the investigator at each site.
|
7 day post procedure to 6 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Atrial Fibrillation Symptom Severity Scores From Baseline to 6 Months
Tidsramme: 6 Months
|
Subjects rated the severity of their AF-related symptoms at baseline and at each follow-up visit for the study.
Symptoms that were assessed at each visit included the presence of palpitations, fatigue, shortness of breath, lightheadedness or dizziness, and/or lack of energy upon exertion or exercise.
Each symptom was rated on a scale from 1 (no symptoms) to 5 (most severe).
Total scores were obtained by adding up the rating for each symptom to obtain a range of results between 5 (asymptomatic) to 25 (severely symptomatic).
|
6 Months
|
|
The Short Form 36 Question (SF-36) Health Survey Quality of Life Survey at 6 Months Compared to Baseline
Tidsramme: 6 months
|
The SF-36 is a short-form health survey of 36 questions that yields an 8-scale health profile as well as psychometrically-based physical and mental health summary measures.
In order to assess improvement in self-perceived quality of life, subjects were asked to complete SF-36 questionnaires at baseline and at each follow-up visit.
The results of the Physical Component and Mental Component scores from the two summary measures that aggregate sub-scales were then compared.The SF-36 subscales range from 0 (lowest) to 100 (highest).
The subscales are averaged together for a total score between 0 to 100.
A higher score represents a better outcome when compared to a lower score.
|
6 months
|
|
Measurement of the Cumulative RF Time for Pulmonary Vein(PV)Isolation of All Accessible Pulmonary Veins
Tidsramme: After Procedure
|
Cumulative RF time was calculated by the difference between the start time of catheter ablations and the end time of the ablation
|
After Procedure
|
|
Total Procedure Time
Tidsramme: End of Procedure
|
Measurement of total procedure time defined as "skin to skin" and left atrial dwell time (transseptal puncture to removal of all left atrial catheters)
|
End of Procedure
|
|
Total Fluoroscopy Time
Tidsramme: Post Ablation Procedure
|
Total time that flouroscopy was used during the ablation procedure.
|
Post Ablation Procedure
|
Samarbejdspartnere og efterforskere
Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.
Samarbejdspartnere
Publikationer og nyttige links
Den person, der er ansvarlig for at indtaste oplysninger om undersøgelsen, leverer frivilligt disse publikationer. Disse kan handle om alt relateret til undersøgelsen.
Hjælpsomme links
Datoer for undersøgelser
Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.
Studer store datoer
Studiestart
1. oktober 2007
Primær færdiggørelse (Faktiske)
1. september 2009
Studieafslutning (Faktiske)
1. juli 2011
Datoer for studieregistrering
Først indsendt
28. august 2008
Først indsendt, der opfyldte QC-kriterier
29. august 2008
Først opslået (Skøn)
1. september 2008
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
19. september 2018
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
17. september 2018
Sidst verificeret
1. september 2018
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- AFI-40
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Paroksysmal atrieflimren
-
TriVirum, Inc.AfsluttetAtrieflimren | Arytmier, hjerte | Paroksysmal atrieflimren | Afib | Uregelmæssig hjerteslag | Arytmi Atrial | Arytmier ParoxysmalForenede Stater
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Pusan National University HospitalIkke rekrutterer endnuHjerteimplanterbar elektronisk enhed | Atrial High Rate EpisodeKorea, Republikken
-
W.L.Gore & AssociatesAfsluttetSeptal defekt, atrialForenede Stater
-
Academisch Medisch Centrum - Universiteit van Amsterdam...Tilmelding efter invitationKortkoblet idiopatisk ventrikulær fibrillationHolland
-
Henry Ford Health SystemTrukket tilbage
-
Centre Hospitalier Universitaire, AmiensHenri Mondor University HospitalRekrutteringSeptisk chok | Kritisk pleje | Transthorax ekkokardiografi | Speckle Tracking | Reproducerbarhed | Venstre atrial belastning | Højre atrial belastning | Ekkokardiografisk softwareFrankrig
-
Assiut UniversityTrukket tilbageASD2 (Secundum atrial septal defekt)
-
First Affiliated Hospital of Ningbo UniversityAfsluttetEvaluering af radiofrekvensoverført punkteringssystem | Atrial septum punkteringKina
-
Prof. Dr. med. Ingo EitelRekrutteringAtrial hypertensionTyskland
Kliniske forsøg med RF Ablation procedure
-
Oxford University Hospitals NHS TrustAfsluttetAtrieflimrenDet Forenede Kongerige
-
Abbott Medical DevicesAfsluttetParoksysmal atrieflimrenTyskland
-
Deutsches Herzzentrum MuenchenCryoCath Technologies Inc.AfsluttetAtrioventrikulær Nodal Reentry TakykardiTyskland
-
Biosense Webster, Inc.AfsluttetParoksysmal atrieflimrenDanmark, Holland, Det Forenede Kongerige, Frankrig, Belgien, Østrig, Irland, Italien, Schweiz
-
Olympus Corporation of the AmericasAfsluttetLungekræft | Metastatisk lungekræftForenede Stater, Canada
-
Washington University School of MedicineAfsluttetOndartede levertumorer | Levermetastaser fra tyktarmskræftForenede Stater
-
Venclose, Inc.AfsluttetKronisk venøs insufficiensTyskland
-
Hospital Clinic of BarcelonaCardioFocusAfsluttetAtrieflimrenSpanien
-
Deutsches Herzzentrum MuenchenUniversity of BergenAfsluttetRadiofrekvensablation | Atrioventrikulær Nodal Reentry TakykardiNorge